Pharmacy Times March 19, 2025
As demand for GLP-1 therapies grows, patients face rising costs and restrictive insurance policies.
As the cost of health care continues to rise, access to life-changing medications remains a pressing issue for patients and providers alike. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as powerful treatments for obesity and type 2 diabetes, with growing potential for additional therapeutic applications. However, despite their clinical benefits, the high cost of these medications—paired with restrictive insurance coverage—has left many patients unable to access them.
This challenge is deeply intertwined with the role of pharmacy benefit managers (PBMs), whose pricing strategies and formulary decisions significantly impact which patients can afford GLP-1 therapies. As policymakers and industry leaders push for PBM reform, the future of...
Today's Sponsors
Today's Sponsor